Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methylergometrine
- Development stage
- Approved
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Intramuscular
01
Overview
Methylergometrine (also known as methylergonovine) is a semi-synthetic ergot alkaloid used primarily in obstetrics to prevent or treat postpartum hemorrhage and uterine atony. It acts as a potent uterotonic by directly stimulating the smooth muscle of the uterus, increasing tone, rate, and amplitude of contractions, thereby reducing blood loss after childbirth or abortion. It is also sometimes used for the prevention and acute treatment of migraine headaches. The drug can be administered orally, intramuscularly, or intravenously. At high doses it may produce psychedelic effects similar to LSD due to its structural similarity as an ergoline derivative[1][2][5]. Methylergometrine is on the World Health Organization's List of Essential Medicines[5].
- Brand names
- Methergine
- Other names
- methylergonovine maleate甲麦角新碱N-[alpha-(Hydroxymethyl)propyl]-D-lysergamidePartergin
02
Targets
ADRA1A (α1A)DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR1B (5-Hydroxytryptamine Receptor 1B)HTR1E (5-hydroxytryptamine receptor 1E)HTR1F (Serotonin 5-HT1F receptor)HTR2A (Serotonin receptor 5-HT2A)HTR2B (5-Hydroxytryptamine Receptor 2B)HTR2C (5-hydroxytryptamine 2C receptor)HTR5A (Serotonin Receptor 5A)HTR7 (5-hydroxytryptamine receptor 7)ADRA1 (Alpha-1 adrenergic receptor family)
Beyond the preview
Go deeper on methylergometrine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methylergometrine.